QSAR modeling, pharmacophore-based virtual screening, and ensemble docking insights into predicting potential epigallocatechin gallate (EGCG) analogs against epidermal growth factor receptor

References

• Rahal Z, Nemr SE, Sinjab A, et al. Smoking and lung cancer: a geo-regional perspective. Front Oncol. 2017;7:194.
   PubMed Web of Science ®Google Scholar
• Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5:288–300.
   PubMed Web of Science ®Google Scholar
• Osada H, Takahashi T. Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Oncogene. 2002;21:7421–7434.
   PubMed Web of Science ®Google Scholar
• Bethune G, Bethune D, Ridgway N, et al. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis. 2010;2:48–51.
   PubMedGoogle Scholar
• Tu CY, Cheng FJ, Chen CM, et al. Cigarette smoke enhances oncogene addiction to c-MET and desensitizes EGFR-expressing non-small cell lung cancer to EGFR TKIs. Mol Oncol. 2018;12:705–723.
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy. Cancer Sci. 2016;107:1179–1186.
   PubMed Web of Science ®Google Scholar
• Nagle DG, Ferreira D, Zhou YD. Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives. Phytochemistry. 2006;67:1849–1855.
   PubMed Web of Science ®Google Scholar
• Du GJ, Zhang Z, Wen XD, et al. Epigallocatechin gallate (EGCG) is the most effective cancer chemopreventive polyphenol in green tea. Nutrients. 2012;4:1679–1691.
   PubMed Web of Science ®Google Scholar
• Adachi S, Shimizu M, Shirakami Y, et al. (-)-Epigallocatechin gallate downregulates EGF receptor via phosphorylation at Ser1046/1047 by p38 MAPK in colon cancer cells. Carcinogenesis. 2009;30:1544–1552.
   PubMed Web of Science ®Google Scholar
• Sah JF, Balasubramanian S, Eckert RL, et al. Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases. J Biol Chem. 2004;279:12755–12762.
   PubMed Web of Science ®Google Scholar
• Lambert JD, Kennett MJ, Sang S, et al. Hepatotoxicity of high oral dose (-)-epigallocatechin-3-gallate in mice . Food Chem Toxicol. 2010;48:409–416.
   PubMed Web of Science ®Google Scholar
• Ramachandran B, Jayavelu S, Murhekar K, et al. Repeated dose studies with pure epigallocatechin-3-gallate demonstrated dose and route dependant hepatotoxicity with associated dyslipidemia. Toxicol Rep. 2016;3:336–345.
   PubMed Web of Science ®Google Scholar
• Parasuraman S. Toxicological screening. J Pharmacol Pharmacother. 2011;2:74.
   PubMedGoogle Scholar
• Bommu UD, Konidala KK, Pamanji R, et al. Structural probing, screening and structure-based drug repositioning insights into the identification of potential Cox-2 inhibitors from selective coxibs. Interdiscip Sci. [cited 2017 Dec 13]. DOI:10.1007/s12539-017-0244-5.
   Web of Science ®Google Scholar
• Raies AB, Bajic VB. In silico toxicology: computational methods for the prediction of chemical toxicity. Wires Comput Mol Sci. 2016;6:147–172.
   Google Scholar
• Sushko I, Pandey A, Novotarskyi S, et al. Online chemical modeling environment (OCHEM): web platform for data storage, model development and publishing of chemical information. J Cheminform. 2011;25:533–554.
   Google Scholar
• Tetko IV, Tanchuk VY, Villa AEP. Prediction ofn-octanol/water partition coefficients from PHYSPROP database using artificial neural networks and E-state indices. J Chem Inf Comput Sci. 2001;41:1407–1421.
   PubMedGoogle Scholar
• Tetko IV, Tanchuk VY, Kasheva TN, et al. Estimation of aqueous solubility of chemical compounds using E-state indices. J Chem Inf Comput Sci. 2001;41:1488–1493.
   PubMedGoogle Scholar
• Kumar KK, Devi BU, Neeraja P. Integration of in silico approaches to determination of endocrine-disrupting perfluorinated chemicals binding potency with steroidogenic acute regulatory protein. Biochem Biophys Res Commun. 2017;491:1007–1014.
   PubMed Web of Science ®Google Scholar
• Wood ER, Truesdale AT, Mcdonald OB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004;64:6652–6659.
   PubMed Web of Science ®Google Scholar
• Wolber G, Langer T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model. 2005;45:160–169.
   PubMed Web of Science ®Google Scholar
• Harris R, Olson AJ, Goodsell DS. Automated prediction of ligand-binding sites in proteins. Proteins. 2008;70:1506–1517.
   PubMed Web of Science ®Google Scholar
• Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods Mol Biol. 2015;1263:243–250.
   PubMedGoogle Scholar
• Bommu UD, Konidala KK, Pabbaraju N, et al. Ligand-based virtual screening, molecular docking, QSAR and pharmacophore analysis of quercetin-associated potential novel analogs against epidermal growth factor receptor. J Recept Signal Transduct Res. 2017;37:600–610.
   PubMed Web of Science ®Google Scholar
• Bommu UD, Konidala KK, Pamanji R, et al. Computational screening, ensemble docking and pharmacophore analysis of potential gefitinib analogues against epidermal growth factor receptor. J Recept Signal Transduct Res. 2018;38:48–60.
   PubMed Web of Science ®Google Scholar
• Singh H, Singh S, Singla D, et al. QSAR based model for discriminating EGFR inhibitors and non-inhibitors using random forest. Biol Direct. 2015;10:10.
   PubMed Web of Science ®Google Scholar
• Singh H, Kumar R, Singh S, et al. Prediction of anticancer molecules using hybrid model developed on molecules screened against NCI-60 cancer cell lines. BMC Cancer. 2016;16:77.
   PubMed Web of Science ®Google Scholar
• OECD. Environmental Directorate. Guidance document on the validation of (Q)SAR models. Paris, France: OECD. Health and Safety Publications. Series on Testing and Assessment; 2007, p. 69.
   Google Scholar
• Donald JE, Kulp DW, DeGrado WF. Salt bridges: geometrically specific, designable interactions. Proteins. 2011;79:898–915.
   PubMed Web of Science ®Google Scholar
• Dougherty DA. The cation-π interaction. Acc Chem Res. 2013;46:885–893.
   PubMed Web of Science ®Google Scholar